ArticleBMC research notes2019
Second-line antiretroviral therapy regimen change among adults living with HIV in Amhara region: a multi-centered retrospective follow-up study.
Article in BMC research notes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Virologic failure and its determinants among HIV patients progress towards the third 95% global target in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Virological failure and risk factors among people living with HIV taking second-line ART in Addis Ababa, Ethiopia.PloS one · 2026Article
- HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon.BMC infectious diseases · 2024Article
- Mortality Risk Factors Among People Living with HIV Receiving Second-line Antiretroviral Therapy in Rural China.Current HIV research · 2024Article
- Effectors of Hyperlipidemia Among Patients with HIV/AIDS Taking Second-line Antiretroviral Therapy Based on Registry Data.Current HIV research · 2022Article
- Effects of Chinese Medicine on the Survival of AIDS Patients Administered Second-Line ART in Rural Areas of China: A Retrospective Cohort Study Based on Real-World Data.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Determinants of Virologic Failure Among Adults on Second Line Antiretroviral Therapy in Wollo, Amhara Regional State, Northeast Ethiopia.HIV/AIDS (Auckland, N.Z.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was conducted to determine the rate of initial second-line ART regimen change and its predictors among adults living with HIV in Amhara region. A retrospective follow-up study was conducted between February, 2008 and April, 2016 at eight governmental hospitals of Amhara region. Person-times and Cox proportional hazard model were fitted to determine the rate and to identify the significant predictors of second-line treatment regimen change.
resultsA total of 897 records of patients were analyzed. The overall rate of initial second-line drug regimen change was 24.2 per 100 person years. The rate of regimen change was decreased for patients with formal education (HR: 0.77, 95% CI 0.61-0.97), under WHO clinical stage-III (HR: 0.57, 95% CI 0.45-0.73), and WHO clinical stage-IV (HR: 0.64, 95% CI 0.43-0.96). Patients who were taking CPT (HR: 2.05, 95% CI 1.45-2.89) had an increased rate of regimen change. Furthermore, the rate of regimen change was decreased for patients who were switched to second-line treatment due to virological failure (HR: 0.36, 95% CI 0.25-0.53), and due to drug toxicity (HR: 0.48, 95% CI 0.28-0.81). Therefore, addressing significant predictors to maximize the durability on the initial regimen among ART clients is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.